Schr_dinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schr_dinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. Schr_dinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company Nimbus Therapeutics. Through significant long-term investments in basic research, Schr_dinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schr_dinger scientists are frequently among the most heavily cited in their fields. Founded in 1990, Schr_dinger has operations in the US, Europe, Japan, and India, with business partners in China and Korea. Products and Services Schr_dinger's full product offerings range from general molecular modeling programs to a comprehensive suite of drug design software, as well as a state-of-the-art suite for materials research. Schr_dinger has also developed enterprise level software that can be deployed throughout an entire research organization. The company is strongly committed to helping its customers realize the full potential benefits of its products through unparalleled support and collaborations. Fast Facts ´ 25+ years of experience developing molecular simulation software ´ Serving customers in 70 countries ´ 300 employees worldwide, 80% technical staff, 50% PhDs ´ Team of 60+ modelers providing modeling services and collaborating on drug discovery projects ´ Over 40 patents held or pending with a Schr_dinger scientist as author ´ 400 commercial customers (including all top 30 pharma companies) and more than 1400 academic and government customers